Home / Investors / Overview

Company Information

CymaBay Therapeutics (NASDAQ: CBAY)

CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough therapies addressing unmet medical needs. Arhalofenate, the company's lead product candidate, possesses two therapeutic actions in a single drug. In gout patients, arhalofenate is intended to prevent painful attacks in joints while at the same time promoting excretion of uric acid by the kidney, thereby removing the root cause of this debilitating disease.

Stock Information

Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7999 Gateway Blvd
Suite 130
Newark, CA 94560

Investor Relations

Sujal Shah
(510) 293-8800

Recent News


CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate


CymaBay Announces Exclusive Licensing Agreement with Kowa Pharmaceuticals America, Inc. for the Development and Commercialization of Arhalofenate in the United States


CymaBay Announces the Appointments of Robert Booth, Ph.D. and Caroline Loewy to Its Board of Directors

Q3 2016 Quarterly Results

Overview Overview